Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

  • STATUS
    Recruiting
  • End date
    Aug 25, 2023
  • participants needed
    280
  • sponsor
    Ferring Pharmaceuticals
Send
Updated on 25 December 2020
See if I qualify
Investigator
Global Clinical Compliance
Primary Contact
OB/Gyn Associates (6.2 mi away) Contact
+54 other location

Summary

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain

Details
Treatment Placebo, Quinagolide 360 µg, Quinagolide 720 µg, Quinagolide 1080 µg
Clinical Study IdentifierNCT03692403
SponsorFerring Pharmaceuticals
Last Modified on25 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you female?
Do you have Endometriosis Related Pain?
Do you have any of these conditions: Do you have Endometriosis Related Pain??
Do you have any of these conditions: Do you have Endometriosis Related Pain??
Do you have any of these conditions: Do you have Endometriosis Related Pain??
Do you have any of these conditions: Do you have Endometriosis Related Pain??
Do you have any of these conditions: Do you have Endometriosis Related Pain??
Do you have any of these conditions: Do you have Endometriosis Related Pain??
Pre-menopausal females aged 18 years at time of signing informed consent(s)
Body mass index (BMI) of 18-42 kg/m2 (both inclusive) at screening
Initial confirmation of endometriosis by laparoscopy or laparotomy within the last 10 years before the run-in visit or visualization of persistent endometrioma by repeat ultrasound
Transvaginal ultrasound documenting a uterus with no clinically significant abnormalities and presence of at least one ovary with no clinically significant abnormalities (with the exception of endometrioma) at the run-in visit
Having moderate to severe endometriosis-related pain
Willing to use a non-hormonal barrier method (i.e. condom) for contraception from randomization to the end-of-trial. This is not required if adequate contraception is achieved by vasectomy of the sexual partner or surgical sterilisation of the subject
Willing to avoid the use of vaginal douches or any other intravaginally administered medications or devices from randomization to the end of treatment
Willing to change usual analgesics to rescue analgesics as permitted by protocol for endometriosis-related pain from the start of run-in to the end-of-trial

Exclusion Criteria

Use of depot medroxyprogesterone acetate (MPA) within 10 months of the start of run-in
Use of gonadotropin releasing hormone (GnRH) agonists (3 months depot) or dopamine agonists within 6 months of the start of run-in
Use of GnRH agonists (1 month depot) or intrauterine device within 3 months of the start of run-in
Use of GnRH antagonist, combined oral contraceptive pill or progestin-only pill within 1 month of the start of run-in
Undiagnosed abnormal vaginal bleeding
History of no relief of endometriosis related pain after any medical therapy or surgery. However, history of partial pain relief, discontinuation due to side effects are not exclusionary
Known bone diseases (e.g. osteoporosis, Paget's disease and osteomalacia) affecting bone resorption or bone formation markers
Any significant abnormal findings of heart examinations before randomization
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name
Edit Delete

Annotated by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet